U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C20H21N
Molecular Weight 275.3874
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CYCLOBENZAPRINE

SMILES

CN(C)CCC=C1C2=C(C=CC=C2)C=CC3=C1C=CC=C3

InChI

InChIKey=JURKNVYFZMSNLP-UHFFFAOYSA-N
InChI=1S/C20H21N/c1-21(2)15-7-12-20-18-10-5-3-8-16(18)13-14-17-9-4-6-11-19(17)20/h3-6,8-14H,7,15H2,1-2H3

HIDE SMILES / InChI

Molecular Formula C20H21N
Molecular Weight 275.3874
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including: https://www.drugs.com/slideshow/flexeril-cyclobenzaprine-muscle-relaxants-1266 | http://www.rxlist.com/flexeril-drug.htm | https://www.ncbi.nlm.nih.gov/pubmed/26926618 | https://www.ncbi.nlm.nih.gov/pubmed/26668287

Cyclobenzaprine is a centrally-acting muscle relaxant which boosts levels of norepinephrine and binds to serotonin receptors in the brain to reduce spasm. Cytochromes P-450 3A4, 1A2, and, to a lesser extent, 2D6, mediate N-demethylation, one of the oxidative pathways for cyclobenzaprine. Cyclobenzaprine relieves skeletal muscle spasm of local origin without interfering with muscle function. Drowsiness, fatigue and sedation (up to 40%) is the most common side effect of Cyclobenzaprine. It may have life-threatening interactions with monoamine oxidase (MAO) inhibitors. Postmarketing cases of serotonin syndrome have been reported during combined use of cyclobenzaprine and other drugs such as selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), tramadol, bupropion, meperidine, verapamil, or MAO inhibitors.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Palliative
CYCLOBENZAPRINE HYDROCHLORIDE

Approved Use

Drug is indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. Improvement is manifested by relief of muscle spasm and its associated signs and symptoms, namely, pain, tenderness, limitation of motion, and restriction in activities of daily living.

Launch Date

1988
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
8.3 ng/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
354.1 ng × h/mL
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
33.4 h
15 mg single, oral
dose: 15 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CYCLOBENZAPRINE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Doses

Doses

DosePopulationAdverse events​
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources: Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources: Page: p.282
Disc. AE: Lethargy, Slurred speech...
AEs leading to
discontinuation/dose reduction:
Lethargy
Slurred speech
Sinus tachycardia
Sources: Page: p.282
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Disc. AE: Sinus tachycardia, Confusion...
AEs leading to
discontinuation/dose reduction:
Sinus tachycardia
Confusion
Drowsiness
Agitation
Visual hallucinations
Sources: Page: p.283
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources: Page: p.1068
unhealthy, 41.5
n = 249
Health Status: unhealthy
Condition: Muscle spasm
Age Group: 41.5
Sex: M+F
Population Size: 249
Sources: Page: p.1068
Disc. AE: Somnolence...
AEs leading to
discontinuation/dose reduction:
Somnolence (5.2%)
Sources: Page: p.1068
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources: Page: p.1
Disc. AE: Serotonin syndrome, Cardiovascular disorder NOS...
AEs leading to
discontinuation/dose reduction:
Serotonin syndrome (grade 4)
Cardiovascular disorder NOS
CNS depression
Sources: Page: p.1
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Other AEs: Tachycardia, Dry mouth...
Other AEs:
Tachycardia (below serious, 1 patient)
Dry mouth (below serious, 6 patients)
Toothache (below serious, 1 patient)
Rhinitis (below serious, 1 patient)
Dizziness (below serious, 1 patient)
Dysgeusia (below serious, 1 patient)
Anxiety (below serious, 1 patient)
Disruptive mood dysregulation disorder (below serious, 1 patient)
Sleep disorder (below serious, 1 patient)
Somnolence (below serious, 18 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Lethargy Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources: Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources: Page: p.282
Sinus tachycardia Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources: Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources: Page: p.282
Slurred speech Disc. AE
900 mg single, oral
Overdose
Dose: 900 mg
Route: oral
Route: single
Dose: 900 mg
Sources: Page: p.282
healthy, 18
n = 1
Health Status: healthy
Age Group: 18
Sex: F
Population Size: 1
Sources: Page: p.282
Agitation Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Confusion Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Drowsiness Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Sinus tachycardia Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Visual hallucinations Disc. AE
600 mg single, oral
Overdose
Dose: 600 mg
Route: oral
Route: single
Dose: 600 mg
Sources: Page: p.283
healthy, 24
n = 1
Health Status: healthy
Age Group: 24
Sex: F
Population Size: 1
Sources: Page: p.283
Somnolence 5.2%
Disc. AE
10 mg 3 times / day multiple, oral
Recommended
Dose: 10 mg, 3 times / day
Route: oral
Route: multiple
Dose: 10 mg, 3 times / day
Sources: Page: p.1068
unhealthy, 41.5
n = 249
Health Status: unhealthy
Condition: Muscle spasm
Age Group: 41.5
Sex: M+F
Population Size: 249
Sources: Page: p.1068
CNS depression Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources: Page: p.1
Cardiovascular disorder NOS Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources: Page: p.1
Serotonin syndrome grade 4
Disc. AE
30 mg 1 times / day multiple, oral
Recommended
Dose: 30 mg, 1 times / day
Route: oral
Route: multiple
Dose: 30 mg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Muscle spasm
Sources: Page: p.1
Anxiety below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Disruptive mood dysregulation disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Dizziness below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Dysgeusia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Rhinitis below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Sleep disorder below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Tachycardia below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Toothache below serious, 1 patient
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Somnolence below serious, 18 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Dry mouth below serious, 6 patients
15 mg 1 times / day steady, oral
Dose: 15 mg, 1 times / day
Route: oral
Route: steady
Dose: 15 mg, 1 times / day
Sources:
unhealthy
n = 90
Health Status: unhealthy
Condition: Cervical and/or Lower Back Pain
Population Size: 90
Sources:
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG


OverviewOther

Other InhibitorOther SubstrateOther Inducer



Drug as victim
PubMed

PubMed

TitleDatePubMed
Cyclobenzaprine and back pain: a meta-analysis.
2001 Jul 9
Clinical inquiries. What is the most effective treatment for acute low back pain?
2002 Feb
Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency.
2002 Jan
Release of cyclobenzaprine hydrochloride from osmotically rupturable tablets.
2002 Jul
Investigation of cyclobenzaprine hydrochloride release from oral osmotic delivery systems containing a water-swellable polymer.
2002 Jul
Management of sleep disorders in fibromyalgia.
2002 May
The effectiveness of adding pharmacologic treatment with clonazepam or cyclobenzaprine to patient education and self-care for the treatment of jaw pain upon awakening: a randomized clinical trial.
2002 Winter
Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials.
2003 Apr
Tricyclic analogs cyclobenzaprine, amitriptyline and cyproheptadine inhibit the spinal reflex transmission through 5-HT(2) receptors.
2003 Jan 1
Fatal cyclobenzaprine overdose with postmortem values.
2003 Jul
The diagnostic and therapeutic challenge of femoral head osteoid osteoma presenting as thigh pain: a case report.
2003 Jun
Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome p450 3A4 substrate, in patients with chronic myeloid leukaemia.
2003 Nov 17
Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculoskeletal conditions: a systematic review.
2004 Aug
Prescription of nonsteroidal anti-inflammatory drugs and muscle relaxants for back pain in the United States.
2004 Dec 1
Treatment of fibromyalgia with cyclobenzaprine: A meta-analysis.
2004 Feb 15
Human liver aldehyde oxidase: inhibition by 239 drugs.
2004 Jan
A randomized clinical trial comparing chiropractic adjustments to muscle relaxants for subacute low back pain.
2004 Jul-Aug
Commonly used muscle relaxant therapies for acute low back pain: a review of carisoprodol, cyclobenzaprine hydrochloride, and metaxalone.
2004 Sep
In vitro screening for inhibitors of the human mitotic kinesin Eg5 with antimitotic and antitumor activities.
2004 Sep
The control of impurities in amitriptyline hydrochloride using a reversed-phase hybrid stationary phase.
2005 Aug
Usage of pain medications during stroke rehabilitation: the Post-Stroke Rehabilitation Outcomes Project (PSROP).
2005 Fall
Atypical antipsychotics in the treatment of fibromyalgia: a case series with olanzapine.
2005 Jan
Effect of cyclobenzaprine on tricyclic antidepressant assays.
2005 Jul-Aug
Prediction of genotoxicity of chemical compounds by statistical learning methods.
2005 Jun
Rhabdomyolysis: a manifestation of cyclobenzaprine toxicity.
2006 Jul 17
Extended-release cyclobenzaprine (Amrix).
2007 Dec 17
In silico prediction of pregnane X receptor activators by machine learning approaches.
2007 Jan
Interpreting tricyclic antidepressant measurements in urine in an emergency department setting: comparison of two qualitative point-of-care urine tricyclic antidepressant drug immunoassays with quantitative serum chromatographic analysis.
2007 Jun
A meta-analysis of the efficacy of fibromyalgia treatment according to level of care.
2008
Cost-utility of an 8-month aquatic training for women with fibromyalgia: a randomized controlled trial.
2008
Leiomyosarcoma of the breast in a patient with a 10-year-history of cyclophosphamide exposure: a case report.
2008 Nov 7
Effects of naltrexone on pain sensitivity and mood in fibromyalgia: no evidence for endogenous opioid pathophysiology.
2009
Comparison of the single-dose pharmacokinetics of once-daily cyclobenzaprine extended-release 30 mg and cyclobenzaprine immediate-release 10 mg three times daily in the elderly: a randomized, open-label, crossover study.
2009
A 19-month-old girl with recurrent illness: over the hills and through the woods.
2009 Dec
Bertolotti's syndrome: a case report.
2009 Mar-Apr
Pharmacotherapy of chronic pain: a synthesis of recommendations from systematic reviews.
2009 May-Jun
Drugs associated with more suicidal ideations are also associated with more suicide attempts.
2009 Oct 2
Patients' experiences of living with and receiving treatment for fibromyalgia syndrome: a qualitative study.
2009 Oct 7
Inappropriate prescribing in the hospitalized elderly patient: defining the problem, evaluation tools, and possible solutions.
2010 Apr 7
Comparison of ibuprofen, cyclobenzaprine or both in patients with acute cervical strain: a randomized controlled trial.
2010 Jan
Antidepressant drugs in oral fluid using liquid chromatography-tandem mass spectrometry.
2010 Mar
Pharmacokinetic profile of once-daily cyclobenzaprine extended-release.
2010 Nov
Patents

Sample Use Guides

5 mg three times a day. Based on individual patient response, the dose may be increased to either 7.5 mg or 10 mg three times a day.
Route of Administration: Oral
In Vitro Use Guide
The iontaphoretic application of Cyclobenzaprine (CBZ) caused, in all cases, a decrease in discharge rate. This slowing was invariably attended by a marked decrease in action potential amplitude however, and was therefore considered likely to be a local anesthetic effect, even at 5 nA. On the other hand, when CBZ was infused into the chamber to a concentration equivalent to 1 mg/kg for the whole animal, assuming distribution in all extracellular water, all cells responded and no local anesthetic effects were evident. The six cells with initial discharge rates between 2 and 10 Hz decreased firing with CBZ, whereas the four cells with initial rates between 0.5 and 1.5 Hz increased their rates with CBZ.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:16:52 GMT 2023
Edited
by admin
on Sat Dec 16 16:16:52 GMT 2023
Record UNII
69O5WQQ5TI
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYCLOBENZAPRINE
INN   MI   VANDF   WHO-DD  
INN  
Official Name English
CYCLOBENZAPRINE [MI]
Common Name English
MK-130 (AS THE BASE)
Code English
Cyclobenzaprine [WHO-DD]
Common Name English
MK-130
Systematic Name English
cyclobenzaprine [INN]
Common Name English
CYCLOBENZAPRINE [VANDF]
Common Name English
CYCLOBENZAPRINE [USP IMPURITY]
Common Name English
N,N-DIMETHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-(SUP .DELTA.5,.GAMMA.)-PROPYLAMINE
Common Name English
TNX-102
Code English
AMITRIPTYLINE HYDROCHLORIDE IMPURITY B [EP IMPURITY]
Common Name English
NORTRIPTYLINE HYDROCHLORIDE IMPURITY E [EP IMPURITY]
Common Name English
1-PROPANAMINE, 3-(5H-DIBENZO(A,D)CYCLOHEPTEN-5-YLIDENE)-N,N-DIMETHYL-
Systematic Name English
3-(5H-DIBENZO(A,D)(7)ANNULEN-5-YLIDENE)-N,N-DIMETHYLPROPAN-1-AMINE
Systematic Name English
Classification Tree Code System Code
NCI_THESAURUS C29696
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
NDF-RT N0000175737
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
NDF-RT N0000175730
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
WHO-VATC QM03BX08
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
LIVERTOX NBK548894
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
WHO-ATC M03BX08
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
Code System Code Type Description
LACTMED
Cyclobenzaprine
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
EVMPD
SUB06849MIG
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
FDA UNII
69O5WQQ5TI
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DRUG CENTRAL
751
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
WIKIPEDIA
CYCLOBENZAPRINE
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-145-8
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
ChEMBL
CHEMBL669
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
MERCK INDEX
m3976
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY Merck Index
IUPHAR
7152
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
SMS_ID
100000083730
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DRUG BANK
DB00924
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
CAS
303-53-7
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
HSDB
8305
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
INN
791
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
MESH
C004704
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
NCI_THESAURUS
C28947
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
CHEBI
3996
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
DAILYMED
69O5WQQ5TI
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
RXCUI
21949
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY RxNorm
PUBCHEM
2895
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
EPA CompTox
DTXSID0046933
Created by admin on Sat Dec 16 16:16:53 GMT 2023 , Edited by admin on Sat Dec 16 16:16:53 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
SALT/SOLVATE -> PARENT
METABOLIC ENZYME -> INHIBITOR
IC50
METABOLIC ENZYME -> SUBSTRATE
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
Related Record Type Details
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
METABOLITE -> PARENT
MAJOR
METABOLITE -> PARENT
METABOLITE -> PARENT
Related Record Type Details
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
PARENT -> IMPURITY
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
PARENT -> IMPURITY
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Route of Elimination PHARMACOKINETIC EXCRETED UNCHANGED, RENAL
PHARMACOKINETIC
PROTEIN BINDING PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC ORAL, EXTENDED-RELEASE
PHARMACOKINETIC
ORAL, EXTENDED-RELEASE (ELDERLY OLDER THAN 65 YEARS)
PHARMACOKINETIC
ORAL BIOAVAILABILITY PHARMACOKINETIC
Tmax PHARMACOKINETIC ORAL, EXTENDED-RELEASE CAPSULE (15 mg DOSE)
PHARMACOKINETIC
ORAL, EXTENDED-RELEASE CAPSULE (30 mg DOSE)
PHARMACOKINETIC